VARENNES, QC, April 19,
2024 /CNW/ - Nora Pharma, a Canadian pharmaceutical
company, has received approval for its first Biosimilar
product.
Nora Pharma, a wholly owned division of Sunshine Biopharma, has
received approval from Health Canada for the commercialization of
NIOPEG® (a pegylated form of filgrastim) in Canada.
"With this product, we demonstrate to the Canadian market our
determination to be a leader in the pharmaceutical sector," said
Malek Chamoun, president of Nora
Pharma. "This is an important milestone for our mission of bringing
high quality affordable medicines to patients across Canada," he added.
NIOPEG® is a Biosimilar comparable to the reference biologic
drug NEULASTA® (pegfilgrastim). NIOPEG® is a long-acting form of
recombinant human granulocyte colony-stimulating factor
(r-HuG-CSF), or filgrastim. It is indicated to decrease the
incidence of infection, as manifested by febrile neutropenia, in
patients with non-myeloid malignancies receiving myelosuppressive
anti-neoplastic drugs. NIOPEG® is available in a pre-filled syringe
of 6 mg/0.6 mL.
"NIOPEG® is used to help prevent infection in people with
non-myeloid cancers who are receiving chemotherapy. An example of a
non-myeloid cancer is breast cancer," said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
"Biosimilars will have a significant impact on the sustainability
of drug insurance plans, ensuring patient access to these
high-quality treatments for years to come.", he continued.
About Nora Pharma Inc.
Nora Pharma is a Canadian pharmaceutical company offering
generic and specialty drugs across the country. Nora Pharma is
positioned as a partner of choice in optimizing the service
offering to pharmacy partners and providing patients with access to
affordable, high quality pharmaceutical products. For more
information, please visit www.norapharma.ca/en/
About Sunshine Biopharma
Inc.
Sunshine Biopharma, through its subsidiary Nora Pharma Inc., has
52 generic prescription drugs on the market in Canada. The Company is planning to expand its
product offering to a total of 60 generic prescription drugs by the
end of 2024. In parallel, Sunshine Biopharma is continuing its
proprietary drug development program which is comprised of (i) K1.1
mRNA for liver cancer, and (ii) PLpro protease inhibitor for SARS
Coronavirus infections. For more information, please visit:
www.sunshinebiopharma.com.
SOURCE Nora Pharma